Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Depreciation & Amortization (CF) (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Depreciation & Amortization (CF) for 14 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 38.36% year-over-year to $1.2 million, compared with a TTM value of $4.9 million through Dec 2025, up 90.75%, and an annual FY2025 reading of $4.6 million, up 96.32% over the prior year.
  • Depreciation & Amortization (CF) was $1.2 million for Q4 2025 at Enanta Pharmaceuticals, down from $1.3 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.3 million in Q3 2025 and bottomed at $479000.0 in Q3 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $797950.0, with a median of $748000.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) plummeted 34.49% in 2022, then surged 168.06% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $780000.0 in 2021, then tumbled by 34.49% to $511000.0 in 2022, then rose by 25.64% to $642000.0 in 2023, then skyrocketed by 38.47% to $889000.0 in 2024, then surged by 38.36% to $1.2 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for ENTA at $1.2 million in Q4 2025, $1.3 million in Q3 2025, and $1.2 million in Q2 2025.